logo: 16th St. Gallen International Breast Cancer Conference

16th St. Gallen International Breast Cancer Conference

Primary Therapy of Early Breast Cancer Vienna, Austria 20 - 23 March 2019

satellite symposia

Wednesday, 20 March 2019

 

10.30 – 12.00 h

Satellite symposium Touchime

What's on the horizon for high risk breast cancer in the adjuvant setting

 

Introduction and welcome – setting the scene
Christoph Zielinski (Austria)

 

Potential of new targeted agents in high-risk early breast cancer – are we entering a new era?
Valentina Guarneri (Italy)

 

Questions from the audience

 

The high-risk early breast cancer patient – how can we apply a differentiated approach in the clinic?

Questions from the audience

Christoph Zielinski (Austria)
François-Clément Bidard (France)

 Looking to the future…
Christoph Zielinski (Austria)

   

12.30 – 14.00h

Satellite symposium Genomic Health


Optimizing outcomes in early-stage breast cancer by tailoring the use of chemotherapy

 

When should we use chemotherapy in early-stage breast cancer?

 

  • Evidence on how to guide chemotherapy treatment decisions
  • A debate around patient cases proposed by a renowned panel

 

Expert Panel:

Ahmad Awada (Belgium)

Joseph Gligorov (France)

Antonio Llombart (Spain)

Ulrike Nitz (Germany)

Eric Winer (USA)

 

 

 

satellite symposia


Thursday, 21 March 2019

 

12.45 – 13.45 h

Satellite symposium Pfizer

 

RAISING THE BAR IN BREAST CANCER CARE:

CDK 4/6 inhibitors


Website prIME Oncology

 

 

Chair: Sibylle Loibl (Germany)  

 

Treating HR+/HER2- breast cancer: CDK4/6 inhibitors today and in the future

Sibylle Loibl (Germany)

 

Clinical benefit of CDK4/6 inhibitors in HR+/HER2- advanced breast cancer – beyond PFS

Nicholas Turner (UK)

 

From trials to clinic: choosing the right treatment for the right patient

Guy Jerusalem (Belgium)

 

Q&A


 

 

17.45 – 19.15 h

Satellite symposium F. Hoffmann-La Roche

 

Transforming the moment: Recent advances in early breast cancer management

 

Website prIME Oncology

Introduction and welcome

Sibylle Loibl (Germany)

 

Optimising treatment for patients with residual disease

Charles Geyer (USA)

 

Targeted therapies to tackle difficult diseases

Aleix Prat (Spain)

 

Transforming our outlook in a curative setting

Sibylle Loibl (Germany)

 

Q&A

 

Summary & close

Sibylle Loibl (Germany)


 

 


 

Friday, 22 March 2019

 

12.45 – 13.45 h

Satellite symposium NanoString Technologies

 

Breakthroughs for HR+/HER2-

Early Breast Cancer Patients: Accurate Risk Measurement and Local Testing with the PAM50 genome signature

 

Accurate risk assessment and value of intrinsic subtyping in practice

Comparison among currently available multigene signatures

Real-world examples of Prosigna relevant to daily practice

Extended benefits from PAM50-based profiling

 

Andreas Makris (UK)

Eva Ciruelos (Spain)

Shani Paluch-Shimon (Israel)

 


 

17.45 – 19.15 h
Satellite symposium prIME Oncology
 
Estrogen Receptor–Positive Early Breast Cancer: 
Developments in HER2+ and Younger Patient Subsets
 
Welcome and introduction
Sibylle Loibl (Germany)
 
Beat the experts interactive quiz
Sibylle Loibl (Germany)
 
The natural history and biology of ER+ breast cancer
Sherene Loi (Australia)
 
Strategies to improve the probability of cure from HER2+ early breast cancer
Javier Cortés (Spain)
 
Premenopausal ER+ breast cancer – Playing the long game
Olivia Pagani (Switzerland)
 
Adverse event management in early breast cancer
Angelo Di Leo (Italy)
 
Balancing benefits and risks in early breast cancer
Sibylle Loibl (Germany)
 
Conclusions and “prIME pointsTM
Sibylle Loibl (Germany)
 

 

 

* The accreditation organisation European Union of Medical Specialists requests that all information about industry related or sponsored satellite symposia has to be mentioned separately from the scientific program.
Rorschacherstr. 150
CH-9006 St. Gallen/Switzerland
Tel. +41 (0)71 243 00 32
Fax. +41 (0)71 245 68 05